Status: Not yet recruiting
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio compared with semaglutide plus matching placebo in adults in China with obesity, albuminuric chronic kidney disease, and without diabetes. Approximately 266 participants will be randomized in a 1:1 ratio. The treatment period will last 24 weeks, followed by a 4-week off-treatment follow-up period.
Participants needed: 266
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University People's HospitalUpdated: Sep 30, 2026
Eligibility criteria
1. Age >=18 years at the time of signing the informed consent form, without gend... [+6]
1. Known allergy to the study drug (active ingredients or excipients) or similar... [+20]